Previous close | 1.0800 |
Open | 1.0800 |
Bid | 1.0100 x 4000 |
Ask | 1.0200 x 4000 |
Day's range | 0.9938 - 1.1000 |
52-week range | 0.9938 - 4.6800 |
Volume | |
Avg. volume | 1,908,729 |
Market cap | 142.167M |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.0700 |
Earnings date | 06 Nov 2023 - 10 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.30 |
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Key Insights Institutions' substantial holdings in Heron Therapeutics implies that they have significant influence over...
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -58.82% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?